Meloxicam, 15 mg/day, spares platelet function in healthy volunteers

Clinical Pharmacology and Therapeutics

Volumn 66, Issue 4, 1999, Pages 425-430

  De Meijer, Arthur ^a   Vollaard, Hans ^a   De Metz, Menno ^a   Verbruggen, Bert ^a   Thomas, Chris ^a   Novakova, Irena ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; COLLAGEN; CYCLOOXYGENASE 2 INHIBITOR; INDOMETACIN; MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; THROMBOXANE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARACHIDONIC ACID; BLOOD PLATELETS; CROSS-OVER STUDIES; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; INDOMETHACIN; MALE; PLATELET AGGREGATION; RADIOIMMUNOASSAY; REFERENCE VALUES; THIAZINES; THIAZOLES; THROMBOXANE B2; TIME FACTORS;

EID: 0032742778     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1053/cp.1999.v66.a101063     Document Type: Article

References (32)

1. 1. Albengres E, Urien S, Barre J, Nguyen P, Brec F, Jolliet P, et al. Clinical pharmacology of oxicams: new insights into the mechanisms of their dose-dependent toxicity. Int J Tissue React 1993;15:125-34.
2. 2. Andrioli G, Lussignoli S, Gaino S, Benoni G, Bellavite P. Study on paradoxical effects of NSAIDs on platelet activation. Inflammation 1997;21:519-30.
3. 3. Brater DC, Anderson S, Baird B, Campbell WB. Effects of ibuprofen, naproxen, and sulindac on prostaglandins in men. Kidney Int 1985;27:66-73.
4. 4. Cook ME, Wallin JD, Thakur VD, Kadowitz PJ, McNamara DB, Garcia MM, et al. Comparative effects of nabumetone, sulindac, and ibuprofen on renal function. J Rheumatol 1997;24:1137-44.
5. 5. Engelhardt G, Bögel R, Schnitzer C, Utzmann R. Meloxicam: influence on arachidonic acid metabolism; part I: in vitro findings. Biochem Pharmacol 1996;51:21-8.
6. 6. Engelhardt G, Homma D, Schlegel K, Utzmann R, Schnitzler C. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favorable gastrointestinal tolerance. Inflamm Res 1995;44:423-33.
7. 7. Kurumbail RG, Stevens AM, Gierse JK, McDonald JJ, Stegeman RA, Pak JY, et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 1996;384:644-7.
8. 8. Vane JR. Towards a better aspirine. Nature 1994;367:215-6.
9. 9. Engelhardt G, Trummlitz G. Biological activity of the main metabolites of meloxicam. Drugs Exp Clin Res 1990;16:53-6.
10. 10. Grossman CJ, Wiseman J, Lucas FS, Trevethick MA, Birch PJ. Inhibition of constitutive and inducible cyclooxygenase activity in human platelets and mononuclear cells by NSAIDs and Cox 2 inhibitors. Inflamm Res 1995;44:253-7.
11. 11. Ogino K, Hatanaka K, Kawamura M, Katori M, Harada Y. Evaluation of pharmacological profile of meloxicam as an anti-inflammatory agent, with particular reference to its relative selectivity for cyclooxygenase-2 over cyclooxygenase-1. Pharmacology 1997;55:44-53.
12. 12. Vane JR. NSAIDs, COX-2 inhibitors, and the gut. Lancet 1995;346:1105-6.
13. 13. Funk CD, Funk LB, Kennedy ME, Pon AS, Fitzgerald GA. Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment. FASEB J 1991;5:2304-12.
14. 14. Barbieri B, Papadogiannakis N, Eneroth P, Söderstedt A, Stain-Malmgren R, Olding LB. P-Aminobenzoic acid, but not its metabolite p-acetamidobenzoic acid, inhibits thrombin induced thromboxane formation in human platelets in a non NSAID-like manner. Thromb Res 1997;86:127-40.
15. 15. Brideau C, Kargman S, Liu S, Dallob AL, Ehrich EW, Rodger IW, et al. A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors. Inflamm Res 1996;45:68-74.
16. 16. Patrono C, Ciabattoni G, Patrignani P, Pugliese F, Filabozzi P, Catella F, et al. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 1985;72: 1177-84.
17. 17. Reilly IAG, Fitzgerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 1987;69:180-6.
18. 18. Freed MI, Audet PR, Zariffa N, Krishna GG, Ilson BE, Everitt DE. Comparative effects of nabumetone, sulindac, and indomethacin on urinary prostaglandin excretion and platelet function in volunteers. J Clin Pharmacol 1994;34:1098-108.
19. 19. Petit AJ, Kort WJ. Plasma eicosanoids and platelet aggregation as parameters to monitor tumor patients. Prostaglandins Leukot Essent Fatty Acids 1988;34:113-8.
20. 20. Kundu SK, Heilman EJ, Sio R, Garcia C, Davidson RM, Ostgaard RA. Description of an in vitro platelet function analyzer - PFA-100. Semin Thromb Hemost 1995;21: 106-12.
21. 21. Mammen EF, Alshameeri RS, Comp PC. Preliminary data from a field trial of the PFA-100 system. Semin Thromb Hemost 1995;21:113-21.
22. 22. Marshall PW, Williams AJ, Dixon RM, Growcott JW, Warburton S, Armstrong J, et al. A comparison of the effects of aspirin on bleeding time measured using the Simplate method and closure time measured using the PFA-100, in healthy volunteers. Br J Clin Pharmacol 1997;44:151-5.
23. 23. Jouzeau JY, Terlain B, Abid A, Nedelec E, Netter P. Cyclo-oxygenase isoenzymes: How recent findings affect thinking about non-steroidal anti-inflammatory drugs. Drugs 1997;53:563-82.
24. 24. Stichtenoth DO, Wagner B, Frölich JC. Effects of meloxicam and indomethacin on cyclooxygenase pathways in healthy volunteers. J Investig Med 1997;45:44-9.
25. 25. Deykin D, Janson P, McMahon L. Ethanol potentiation of aspirin-induced prolongation of the bleeding time. N Engl J Med 1982;14:852-4.
26. 26. Thomas CM, van den Berg RJ, de Koning Gans HJ, Lequin RM. Radioimmunoassays for prostaglandins; I: technical validation of prostaglandin F2α measurements in human plasma using sephadex G-25 gelfiltration. Prostaglandins 1978;15:839-47.
27. 27. Thomas CM, van den Berg RJ, de Koning Gans HJ, Lequin RM. Radioimmunoassays for prostaglandins; II: measurement of prostaglandin E2 and the 13,14-dihydro-15-keto metabolites of the E and F series - description of a reliable technique with a universal applicability. Prostaglandins 1978;15:849-55.
28. 28. Postma CT, de Boo T, Thomas CM, Thien T. Urinary prostaglandin and prostaglandin metabolite excretion in patients with essential hypertension or hypertension with renal artery stenosis. Neth J Med 1995;47:99-105.
29. 29. Kundu SK, Heilman EJ, Sio R, Garcia C, Ostgaard RA. Characterization of an in vitro platelet function analyzer, PFA-100. Clin Appl Thromb Memost 1996;2:241-9.
30. 30. Gorman R, Gorman L, Peterson D, Sun F, Miller O, Fitzpatrick F. Inhibition of human thromboxane synthetase by 9,11-azoprosta-5,13-dienoic acid. Proc Natl Acad USA 1977;74:4007-9.
31. 31. Hawkey C, Kahan A, Steinbruck K, Alegre C, Baumelou E, Begaud B, et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment [published erratum appears in Br J Rheumatol 1998 Oct;37:1142]. Br J Rheumatol 1998;37:937-45.
32. 32. Dequeker J, Hawkey C, Kahan A, Steinbruck K, Alegre C, Baumelou E, et al. Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthritis. Br J Rheumatol 1998;37:946-51.